inclusion criteria: * must be ≥18 years at the time of signing the informed consent * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures * able to adhere to the study visit schedule and other protocol requirements * mild covid-19 with outpatient management as decided by the treating physician * early warning score for 2019-ncov infected patients ≤ 5 * females of childbearing potential (fcbp1) must agree * to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe * to abstain from breastfeeding during study participation and 28 days after study drug discontinuation * all subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment * all subjects must agree not to share medication

inclusion criteria: * must be ≥18 years at the time of signing the informed consent * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures * able to adhere to the study visit schedule and other protocol requirements * mild covid-19 with outpatient management as decided by the treating physician * early warning score for 2019-ncov infected patients ≤ 5 * females of childbearing potential (fcbp1) must agree * to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe * to abstain from breastfeeding during study participation and 28 days after study drug discontinuation * all subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment * all subjects must agree not to share medication

inclusion criteria: - must be ≥18 years at the time of signing the informed consent - understand and voluntarily sign an informed consent document prior to any study related assessments/procedures - able to adhere to the study visit schedule and other protocol requirements - mild covid-19 with outpatient management as decided by the treating physician - early warning score for 2019-ncov infected patients ≤ 5 - females of childbearing potential (fcbp1) must agree - to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe - to abstain from breastfeeding during study participation and 28 days after study drug discontinuation - all subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment - all subjects must agree not to share medication

inclusion criteria: - must be ≥18 years at the time of signing the informed consent - understand and voluntarily sign an informed consent document prior to any study related assessments/procedures - able to adhere to the study visit schedule and other protocol requirements - mild covid-19 with outpatient management as decided by the treating physician - early warning score for 2019-ncov infected patients ≤ 5 - females of childbearing potential (fcbp1) must agree - to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe - to abstain from breastfeeding during study participation and 28 days after study drug discontinuation - all subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment - all subjects must agree not to share medication